GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY26 results · Jul–Sep 2025
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹979.94 crore (down 3.1% from Q2 FY25) and net profit of ₹257.49 crore (up 2.0% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 979.94 | 1,010.77 | −3.1% | 805.17 | +21.7% |
| Other income | 33.57 | 34.54 | −2.8% | 43.72 | −23.2% |
| Total income | 1,013.51 | 1,045.31 | −3.0% | 848.89 | +19.4% |
| Profit before tax | 354.00 | 343.81 | +3.0% | 278.98 | +26.9% |
| Net profit for the period | 257.49 | 252.50 | +2.0% | 205.01 | +25.6% |
| EPS, basic (₹) | 15.07 | 14.67 | +2.7% | 12.10 | +24.5% |
| Net margin (%) | 26.3 | 25.0 | 25.5 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 973.63 | 1,000.05 | −2.6% | 804.83 | +21.0% |
| Other income | 31.27 | 32.19 | −2.9% | 43.76 | −28.5% |
| Total income | 1,004.90 | 1,032.24 | −2.6% | 848.59 | +18.4% |
| Profit before tax | 350.65 | 338.70 | +3.5% | 278.57 | +25.9% |
| Net profit for the period | 255.00 | 248.69 | +2.5% | 204.70 | +24.6% |
| EPS, basic (₹) | 14.92 | 14.45 | +3.3% | 12.08 | +23.5% |
| Net margin (%) | 26.2 | 24.9 | 25.4 |
Consolidated
- Filed with BSE
- 06 Nov 2025, 18:16 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2025, 18:16 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE